Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

VEAT

Laboratory Testing — UK Athlete Blood and Urine Testing

  • First published: 20 January 2021
  • Last modified: 20 January 2021

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
Published by:
UK Anti-Doping
Authority ID:
AA79038
Publication date:
20 January 2021
Deadline date:
-
Notice type:
VEAT
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
No

Abstract

UKAD is an active participant in the global fight against doping in sport and is the national body responsible for creating a UK-wide environment of confidence in clean sport. In the UK, UKAD ensures that sports bodies comply with the World Anti-Doping Code through implementation and management of the UK’s National Anti-Doping Policy.

A significant part of ensuring such compliance is the implementation of a robust testing regime. Since 2009, UKAD has outsourced its blood and urine testing requirements in respect of professional athletes to the King’s College London Drug Control Centre (DCC), the only laboratory in the UK which holds a World Anti-Doping Agency (WADA) accreditation. This arrangement is due to expire in March 2021 and therefore UKAD wishes to finalise its arrangements in respect of the next iteration of this contract.

In terms of the scope of the new contract, it is envisaged that this will be made up of an initial duration of 3 years, followed by the option to renew the contract for a further three 1-year extensions. In terms of contract value, UKAD estimates that this will be approximately GBP 2 million per year.

In light of the fact that:

(i) A laboratory utilised to perform such testing must hold a WADA accreditation (as stipulated by WADA). In the event that UKAD did undertake an open competition, candidates would be required to self-certify that if identified as the successful bidder, the laboratory from which the services would be performed (a laboratory which must be based within the UK as explained below) will have in place a current WADA accreditation at contract award. UKAD understands that securing accreditation could be prohibitively expensive when compared against the contract value and further, that the process could take as long as 2 years to complete. This would not leave sufficient time for a non-accredited supplier to mobilise between contract award and commencement of the services.

And

(ii) Such laboratory needs to be located in the UK to ensure that tests can be transported quickly from the site at which the sample is taken from the athlete to the laboratory (to avoid degradation of the sample), UKAD’s view is that no other entity, other than DCC, could fulfil the contract requirements. To that end, UKAD intends to utilise the negotiated procedure without prior publication of a contract notice to agree arrangements with DCC for the next iteration of the contract, in accordance with regulation 32(2)(b)(ii) of the Public Contracts Regulations 2015 (PCRs) (i.e. competition is absent for technical reasons).

For reference, prior to commencing the procedure described above, UKAD published a prior information notice in the Official Journal of the European Union (reference: 2020/S 247-615593) to establish whether any alternative/viable suppliers exist. As a result of that exercise, UKAD is confident it has established that only DCC can fulfil the contract requirements.

UKAD has set out its further analysis below, so that readers have a fuller understanding of why UKAD believes that the circumstances justify use of the negotiated procedure without prior publication of a contract notice.

Full notice text

Voluntary ex ante transparency notice

Directive 2014/24/EU

Section I: Contracting entity

I.1) Name and addresses

UK Anti-Doping

6990867

Fleetbank House, 2-6 Salisbury Square

London

EC4Y 8AE

UK

Contact person: Philip Bunt

Telephone: +44 2078423489

E-mail: philip.bunt@ukad.org.uk

NUTS: UKI31

Internet address(es)

Main address: www.ukad.org.uk

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Recreation, culture and religion

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Laboratory Testing — UK Athlete Blood and Urine Testing

Reference number: 2020/S 247-615593

II.1.2) Main CPV code

92620000

 

II.1.3) Type of contract

Services

II.1.4) Short description

United Kingdom Anti-Doping Ltd (UKAD) is a non-departmental public body accountable to Parliament through the Department for Digital, Culture, Media and Sport. UKAD is the UK National Anti-Doping Organisation and provides testing services as well as case management, anti-doping intelligence and education services. UKAD requires the services of a laboratory to analyse UK athletes’ urine and blood samples in accordance with the World Anti-Doping Code. After conducting further consultation with the market, UKAD believes that only one entity can fulfil UKAD’s requirements in relation to this contract, the King’s College London Drug Control Centre (DCC). To that end, UKAD intends to enter into a negotiation with DCC pursuant to regulation 32(2)(b)(ii) of the Public Contracts Regulations 2015.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 12 000 000.00  GBP

II.2) Description

II.2.2) Additional CPV code(s)

71600000

71610000

71900000

73111000

II.2.3) Place of performance

NUTS code:

UKI


Main site or place of performance:

London.

II.2.4) Description of the procurement

UKAD is an active participant in the global fight against doping in sport and is the national body responsible for creating a UK-wide environment of confidence in clean sport. In the UK, UKAD ensures that sports bodies comply with the World Anti-Doping Code through implementation and management of the UK’s National Anti-Doping Policy.

A significant part of ensuring such compliance is the implementation of a robust testing regime. Since 2009, UKAD has outsourced its blood and urine testing requirements in respect of professional athletes to the King’s College London Drug Control Centre (DCC), the only laboratory in the UK which holds a World Anti-Doping Agency (WADA) accreditation. This arrangement is due to expire in March 2021 and therefore UKAD wishes to finalise its arrangements in respect of the next iteration of this contract.

In terms of the scope of the new contract, it is envisaged that this will be made up of an initial duration of 3 years, followed by the option to renew the contract for a further three 1-year extensions. In terms of contract value, UKAD estimates that this will be approximately GBP 2 million per year.

In light of the fact that:

(i) A laboratory utilised to perform such testing must hold a WADA accreditation (as stipulated by WADA). In the event that UKAD did undertake an open competition, candidates would be required to self-certify that if identified as the successful bidder, the laboratory from which the services would be performed (a laboratory which must be based within the UK as explained below) will have in place a current WADA accreditation at contract award. UKAD understands that securing accreditation could be prohibitively expensive when compared against the contract value and further, that the process could take as long as 2 years to complete. This would not leave sufficient time for a non-accredited supplier to mobilise between contract award and commencement of the services.

And

(ii) Such laboratory needs to be located in the UK to ensure that tests can be transported quickly from the site at which the sample is taken from the athlete to the laboratory (to avoid degradation of the sample), UKAD’s view is that no other entity, other than DCC, could fulfil the contract requirements. To that end, UKAD intends to utilise the negotiated procedure without prior publication of a contract notice to agree arrangements with DCC for the next iteration of the contract, in accordance with regulation 32(2)(b)(ii) of the Public Contracts Regulations 2015 (PCRs) (i.e. competition is absent for technical reasons).

For reference, prior to commencing the procedure described above, UKAD published a prior information notice in the Official Journal of the European Union (reference: 2020/S 247-615593) to establish whether any alternative/viable suppliers exist. As a result of that exercise, UKAD is confident it has established that only DCC can fulfil the contract requirements.

UKAD has set out its further analysis below, so that readers have a fuller understanding of why UKAD believes that the circumstances justify use of the negotiated procedure without prior publication of a contract notice.

II.2.5) Award criteria

Criteria below:

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Negotiated procedure without prior publication

Justification for selected award procedure:

The works, supplies or services can be provided only by a particular economic operator for the following reason: absence of competition for technical reasons

Explanation:

As described in section II.2.4) above, UKAD believes that in respect of this opportunity, competition is absent for technical reasons, as:

WADA accreditation would be a pre-requisite.

The services must be performed within the UK — UKAD is aware that there are other suppliers outside of the UK which provide similar services to DCC and whose laboratories hold WADA accreditation. However, due to the timescales involved in transporting blood samples to a laboratory outside of the UK (which essentially spoil after a period of 48 hours), UKAD believes it would be impossible to work with such suppliers in practice. This is a particular concern post 1 January 2021, where it appears very likely that delays at the UK border could result in the degradation of blood samples. Such samples can also be taken at various locations within the UK, not all of which are within easy access to a port. If a sample is analysed after the expiry of the minimum timescales stipulated by WADA, this could result in UKAD being unable to prosecute an athlete notwithstanding the fact that there are indications that they may have utilised performance enhancing drugs. It seems likely therefore that a non-UK based supplier, interested in this opportunity, would be required to establish a laboratory within the UK and obtain a separate WADA accreditation in respect of that laboratory to perform the contract. For the reasons stated above, UKAD believes that it would not be commercially viable, or possible within the timescales, for a non-UK based supplier to adopt this approach.

Separation of blood samples and urine samples: while the timescales related to analysing urine samples are much more flexible, UKAD would not be able to separately award contracts for blood sample analysis and urine sample analysis. This is because in order to receive WADA accreditation, a laboratory must undertake a programme which analyses at least 3 000 samples per year. If a laboratory analysed only one type of sample (e.g. blood samples), the quantity would not be sufficient to meet the minimum 3 000 samples required. While there may be certain periods when the laboratory may be testing a high number of blood samples which may exceed 3 000, this would constitute an exceptional scenario. Therefore, UKAD would not be able to guarantee a minimum sample volume will be processed through the supplier’s (UK) laboratory, in order for that laboratory to retain its WADA accreditation. As a result, dividing the contract into two separate contracts (i.e. one contract to process blood samples and another contract to process urine samples) does not present a viable option for UKAD.

In terms of the consequences of utilising a laboratory which was not accredited by WADA, or the WADA accreditation was withdrawn, this would invalidate the UK's testing programme and it is highly likely that the UK would not be in a position to host international sporting events which in turn, would give rise to significant economic and political consequences.

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2020/S 247-615593

Section V: Award of contract/concession

V.2 Award of contract/concession

V.2.1) Date of conclusion of the contract/concession

14/01/2021

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Drug Control Centre, King’s College, University of London

N/A established under Royal Charter & an exempt charity, therefore no national registration number

Franklin-Wilkins Building, 150 Stamford Street

London

SE1 9NH

UK

Telephone: +44 2078484848

E-mail: adrian.1.smith@kcl.ac.uk

Fax: +44 2078484980

NUTS: UKI

Internet address(es)

URL: https://www.kcl.ac.uk/lsm/research/divisions/aes/research/Kings-Forensics/groups/dcc

The contractor is an SME: No

V.2.4) Information on value of the concession and main financing terms (excluding VAT)

Initial estimated total value of the contract/lot/concession: 12 000 000.00 GBP

Total value of the concession/lot: 12 000 000.00  GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

Any review proceedings should be promptly brought to the attention of Philip Bunt, Chief Operating Officer, UK Anti-Doping, Fleetbank House, 2-6 Salisbury Square, London, EC4Y 8AE, and will be dealt with in accordance with the requirements of the Public Contracts Regulations 2015 (PCR). Any review proceedings must be brought within the timescales specified by the applicable law, including, without limitation, the PCR.

VI.4) Procedures for review

VI.4.1) Review body

High Court of England and Wales

London

WC2A 2LL

UK

Telephone: +44 2079477882

Internet address(es)

URL: http://www.justice.gov.uk

VI.4.2) Body responsible for mediation procedures

High Court of England and Wales

London

WC2A 2LL

UK

Telephone: +44 2079477882

Internet address(es)

URL: http://www.justice.gov.uk

VI.5) Date of dispatch of this notice

15/01/2021

Coding

Commodity categories

ID Title Parent category
71610000 Composition and purity testing and analysis services Technical testing, analysis and consultancy services
71900000 Laboratory services Architectural, construction, engineering and inspection services
73111000 Research laboratory services Research services
92620000 Sport-related services Sporting services
71600000 Technical testing, analysis and consultancy services Architectural, construction, engineering and inspection services

Delivery locations

ID Description
100 UK - All

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

About the buyer

Main contact:
philip.bunt@ukad.org.uk
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.